亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

A multicenter randomized phase II study of nivolumab in combination with gemcitabine/cisplatin or ipilimumab as first-line therapy for patients with advanced unresectable biliary tract cancer.

医学 无容量 吉西他滨 易普利姆玛 内科学 肿瘤科 人口 无进展生存期 临床研究阶段 进行性疾病 胃肠病学 癌症 外科 化疗 免疫疗法 环境卫生
作者
Vaibhav Sahai,Kent A. Griffith,Mark M. Zalupski
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:36 (4_suppl): TPS541-TPS541 被引量:3
标识
DOI:10.1200/jco.2018.36.4_suppl.tps541
摘要

TPS541 Background: Patients (pts) with advanced biliary tract cancers (BTC) have poor prognosis with a median overall survival (OS) less than 12 months. This randomized, multi-institutional, phase 2, two-arm study is designed to investigate the role of combinational immunotherapy, using nivolumab with chemotherapy (gemcitabine/cisplatin) or as dual immunotherapy (nivolumab and ipilimumab) in pts with advanced BTC. Methods: Key eligibility criteria include histologically confirmed advanced, unresectable biliary adenocarcinoma (intrahepatic or extrahepatic and gallbladder) without prior systemic treatment, measurable disease per RECISTv1.1, ECOG PS 0-1, and absence of autoimmune disease and/or chronic steroid use. Primary objective is to evaluate the progression-free survival (PFS) rate at 6 months. Secondary objectives include evaluation of overall response rate (ORR), median PFS and OS and safety in this patient population. Exploratory objectives include identification of biomarker predictors of response and mechanisms of resistance through serial (before, on and post therapy) biopsies and blood collection, including sequential whole exome/transcriptomic analysis and immune cell subset analysis (tissue and blood). Arm A therapy provides gemcitabine 1000 mg/m 2 , cisplatin 25 mg/m 2 on days 1, 8 with nivolumab 360 mg on day 1 every 3 weeks for 6 months. In the absence of disease progression, pts may continue single agent nivolumab for up to 2 years. Arm B therapy includes nivolumab 240 mg every 2 weeks and ipilimumab 1 mg/kg every 6 weeks for up to 2 years in absence of disease progression. Accrual goal is 32 evaluable pts per arm. Using a null hypothesis value of 59% median PFS at 6 months, and an 80% alternative hypothesis, this ongoing study has > 80% power, with a one-sided alpha of 0.05 to identify treatment efficacy in one or both study arms. Clinical trial information: NCT03101566.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
萌yxy发布了新的文献求助10
1秒前
传奇3的应助被甜甜的悲采纳,获得10
8秒前
结实的寄柔完成签到,获得积分10
10秒前
14秒前
15秒前
smithsmiles完成签到 ,获得积分20
16秒前
18秒前
迷人宛亦发布了新的文献求助10
19秒前
共享精神的应助被DRJ采纳,获得10
20秒前
顺利手链完成签到,获得积分10
24秒前
24秒前
26秒前
33秒前
34秒前
在水一方的应助被甜甜的悲采纳,获得10
34秒前
可爱多婷婷子完成签到 ,获得积分10
35秒前
35秒前
冷酷的祥完成签到,获得积分10
36秒前
刘承昭发布了新的文献求助10
39秒前
白rain完成签到,获得积分10
41秒前
wanci的应助被刘承昭采纳,获得10
42秒前
45秒前
46秒前
CipherSage的应助被DRJ采纳,获得10
47秒前
PennPeak完成签到,获得积分10
47秒前
甜甜的悲发布了新的文献求助10
49秒前
甜甜的悲发布了新的文献求助10
49秒前
49秒前
甜甜的悲发布了新的文献求助10
51秒前
甜甜的悲发布了新的文献求助10
52秒前
52秒前
甜甜的悲发布了新的文献求助10
52秒前
52秒前
甜甜的悲发布了新的文献求助10
53秒前
53秒前
53秒前
甜甜的悲发布了新的文献求助10
55秒前
55秒前
甜甜的悲发布了新的文献求助10
55秒前
55秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8165968
求助须知:如何正确求助?哪些是违规求助? 9559396
关于积分的说明 21749984
捐赠科研通 7756746
什么是DOI,文献DOI怎么找? 3429092
关于科研通互助平台的介绍 2553386
邀请新用户注册赠送积分活动 2473667